Bristol-Myers wins bragging rights over IBM

IBM_Office_alamy_230x153
By David Rothnie
09 May 2019

The US corporate bond market caught fire this week, as two huge M&A financings - $19bn for Bristol-Myers Squibb and $20bn for IBM - were priced on successive days, and met contrasting fortunes.

Bristol Myers-Squibb printed the biggest deal of 2019 with its $19bn nine tranche issue on Tuesday to fund its acquisition of Celgene. The record lasted for just 24 hours until IBM pipped it with a $20bn eight trancher to finance its purchase of Red Hat.

But the similarities ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.